Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line

Journal of Immunology

Volumn 157, Issue 2, 1996, Pages 787-797

  Fleischhauer, Katharina ^a   Tanzarella, Silvia ^a   Wallny, Hans Joachim ^b,c   Bordignon, Claudio ^a   Traversari, Catia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b BASEL INSTITUTE FOR IMMUNOLOGY   (Switzerland)

^c BIOTEST AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; HLA A ANTIGEN; HLA A2 ANTIGEN; MELANOMA ANTIGEN; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR;

ALLELE; ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOBLAST; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR ASSOCIATED LEUKOCYTE;

ALLELES; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE; HLA-A2 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029958449     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Van der Bruggen, P., C. Traversari, P. Chmez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643.
2. Boon, T., J. C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337.
3. Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167.
4. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.
5. Wang, R. F., P. F. Robbins, Y. Kawakami, X. Q. Kang, and S. A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:799.
6. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
7. + melanoma. J. Exp. Med. 178:489.
8. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. Rosenberg. 1994. Cloning of a gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
9. Coulie, P. G., V. Brichard, A. Van Pel, T. Woelfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J.-P. Szikora, J.-P. Renault, and T. Boon. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
10. Aebersold, P., C. Hyatt, S. Johnoson, K. Hines, L. Korcak, M. Sanders, M. Lotze, S. Topalian, J. Yang, and S. A. Rosenberg. 1991. Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst. 83:932.
11. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. Topalian, S. Toy, P. Simon, M. Lotze, J. Yang, C. Seipp, C. Simpson, C. Carter, S. Boch, D. Schwartzentruber, J. Wei, and D. White. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319:1676.
12. Kawakami, Y., S. Eliyahu, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
13. Traversari, C., P. van der Bruggen, I. F. Leuscher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
14. Gauler, B., B. Van den Eyde, P. van der Bruggen, P. Romero, J. J. Gaforio, E. de Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on melanoma cell by autologous cytolytic lymphocytes. J. Exp. Med. 179:921.
15. Celis, E., V. Tsai, C. Crimi, R. DeMars, P. A. Wentworth, R. W. Chesnut, H. M. Grey, A. Sette, and H. M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105.
16. Van der Bruggen, P., J. P. Szikfara, P. Boel, C. Wildmann, M. Somville, M. Sensi, and T. Boon. 1994. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur. J. Immunol. 24:2134.
17. Van der Bruggen, P., J. Bastin, T. Gajewski, P. Coulie, P. Boel, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induced cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 12:3038.
18. + cytotoxic T lymphocytes. J. Exp. Med. 181:363.
19. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257.
20. Woelfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K. H. Meyer zum Bueschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759.
21. Sykulev, Y., A. Brunmark, M. Jackson, R. J. Cohen, P. A. Peterson, and H. N. Eisen. 1994. Kinetics and affinity of reactions between an antigen-specific T cell recpetor and peptide-MHC complexes. Immunity 1:15.
22. Sykulev, Y., A. Brunmark, T. J. Tsomides, S. Kageyama, M. Jackson, P. A. Peterson, and H. N. Eisen. 1994. High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. Proc. Natl. Acad. Sci. USA 91:11487.
23. Kageyama, S., T. J. Tsomides, Y. Sykulev, and H. N. Eisen. 1995. Variations in the number of peptide-MHC class I complexes required to activate cytolytic T cell responses. J. Immunol. 154:567.
24. Matsui, K., J. J. Boniface, P. A. Reay, H. Schild, B. Fazekas de St. Groth, and M. M. Davis. 1991. Low affinity interaction of peptide MHC complexes with T cell receptors. Science 254:1788.
25. Weber, S., A. Traunecker, F. Oliveri, W. Gerhard, and K. Karjalainen. 1992. Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor. Nature 356:746.
26. Krausa, P., M. Brywka III, D. Savage, K. M. Hui, M. Bunce, J. L. F. Ngai, D. L. T. Teo, Y. W. Ong, D. Barouch, C. E. M. Allsop, A. V. S. Hill, A. J. McMichael, J. G. Bodmer, and M. J. Browning. 1995. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 45:223.
27. Fernandez-Vina, M. A., M. Falco, Y. Sun, and P. Stastny. 1992. DNA typing for HLA class I alleles. I. Subsets of HLA-A2 and of -A28. Hum. Immunol. 33:163.
28. Lopez de Castro, J. A. 1989. HLA-B27 and HLA-A2 subtypes: structure, evolution and function. Immunol. Today 10:239.
29. Imanishi, T., T. Akaza, A. Kimura, K. Tokunaga, and T. Gojobori. 1992. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In HLA 1991. Proceedings of XIth International Histocompatibility Workshop and Conference, Vol 1. K. Tsuji, M. Aizawa, and T. Sasazuki, eds. Oxford University Press, London, p. 1065.
30. Bodmer, J. G., S. G. E. Marsh, E. D. Albert, W. F. Bodmer, R. E. Bontrop, D. Charron, B. Dupont, H. A. Erlich, B. Mach, W. R. Mayr, P. Parham, T. Sasazuki, G. M. T. Schreuder, J. L. Strominger, A. Svejgaard, and P. Terasaki. 1995. Nomenclature for factors of the HLA system, 1995. Hum. Immunol. 43: 149.
31. Fleischhauer, K., E. Zino, B. Mazzi, G. M. Severini, E. Benazzi, and C. Bordignon. HLA-A*02 subtype distribution in Caucasians from northern Italy: identification of A*0220. Tissue Antigens. In press.
32. Bjorkman, P. J., M. A. Saper, B. Samaroui, W. S. Bennett, J. L. Strominger, and D. C. Wiley. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506.
33. Bjorkman, P. J., M. A. Saper, B. Samaroui, W. S. Bennett, J. L. Strominger, and D. C. Wiley. 1987. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 329:512.
34. Saper, M. A., P. J. Bjorkman, and D. C. Wiley. 1991. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J. Mol. Biol. 219:277.
35. Roetzschke, O., K. Falk, S. Stevanovic, G. Jung, and H. G. Rammensee. 1992. Peptide motifs of closely related HLA class I molecules encompass substantial differences. Eur. J. Immunol. 22:2453.
36. Tanigaki, N., D. Fruci, A. Chersi, G. Falasca, R. Tosi, and R. H. Butler. 1994. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. Hum. Immunol. 39:155.
37. Del Guercio, M. F., J. Sidney, G. Hermanson, C. Perez, H. M. Grey, R. T. Kubo, and A. Sette. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154:685.
38. Santos-Aguado, J., M. A. V. Crimmins, S. J. Mentzer, S. J. Burakoff, and J. L. Strominger. 1989. Alloreactivity studied with mutants of HLA-A2. Proc. Natl. Acad. Sci. USA 86:8936.
39. Tekolf, W. A., W. E. Biddison, R. D. Aster, and S. Shaw. 1982. Two subgroups of HLA-Bw44 defined by cell-mediated lympholysis that differ in Bw44 expression on platelets and in patterns of genetic linkage disequilibrium. J. Immunol. 129:1474.
40. Biddison, W. E., D. D. Kostyu, J. L. Strominger, and M. S. Krangel. 1982. Delineation of immunologically and biochemically distinct HLA-A2 antigens. J. Immunol. 129:730.
41. Yang, S. Y. 1989. Population analysis of class I HLA-antigens by one-dimensional isoelectric focusing gel electrophoresis: workshop summary report. In Immunobiology of HLA, Vol.1. B. Dupont, ed. Springer Verlag, Berlin, p. 54.
42. Mattson, D. H., N. Shimojo, E. P. Cowan, J. J. Baskin, R. V. Turner, B. D. Shvetsky, J. E. Coligan, W. L. Maloy, and W. E. Biddison. 1989. Differential effects of amino acid substitutions in the β-sheet floor and α-2 helix of HLA-A2 on recognition by alloreactive viral peptide-specific cytotoxic T lymphocytes. J. Immunol. 143:1101.
43. McMichael, A. J., F. M. Gotch, J. Santos-Aguado, and J. L. Strominger. 1988. Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85:9194.
44. Matsui, M., R. J. Moots, R. J. Warburton, A. L. Peace-Brewer, L. G. Tussey, D. G. Quinn, A. J. McMichael, and J. A. Freilinger. 1995. Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. J. Immunol. 154:1088.
45. Brooks, J. M., R. J. Murray, W. A. Thomas, M. G. Kurilla, and A. B. Rickinson. 1993. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J. Exp. Med. 178:879.
46. Burrows, S. R., R. Khanna, J. M. Burrows, and D. J. Moss. 1994. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J. Exp. Med. 179:1155.
47. Gausepohl, H., M. Kraft, C. Boulin, and R. W. Frank. 1990. Peptides: Chemistry, Structure, Biology. J. Rivier and G. R. Marshall, eds. Essom, Leiden, p. 1003.
48. Woelfel, T., E. Klehmann, C. Mueller, K. H. Schuett, K. H. Meyer zum Bueschenfelde, and A. Knuth. 1989. Lysis of human melanoma cells by autologous cytolytic T cell clones. J. Exp. Med. 170:797.
49. Oh, S. H., K. Fleischhauer, and S. Y. Yang. 1993. Isoelectric focusing subtypes of HLA-A can be defined by oligonucleotide typing. Tissue Antigens 41:135.
50. Parham, P., and F. M. Brodsky. 1981. Partial purification and some properties of BB7.2: a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3:277.
51. McMichael, A. J., P. Parharn, N. Rust, and F. M. Brodsky. 1980. A monoclonal antibody that recognizes an antigenic determinant shared by HLA-A2 and B17. Hum. Immunol. 1:121.
52. Mavilio, F., G. Ferrari, S. Rossini, N. Nobili, C. Bonini, G. Casorati, C. Traversari, and C. Bordignon. 1994. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 83:1988.
53. Herman, J., P. van der Bruggen, I. F. Luescher, S. Mandruzzato, P. Romero, J. Thonnard, K. Fleischhauer, T. Boon, and P. G. Coulie. 1996. A peptide encoded by human gene MAGE-3 and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Immunogenitics. In press.
54. d-restricted cytotoxic T lymphocytes. J. Exp. Med. 173:849.
55. Sensi, M., C. Traversari, M. Radrizzani, S. Salvi, C. Maccalli, R. Mortarini, L. Rivoltini, C. Farina, G. Nicolini, T. Woelfel, B. Brichard, T. Boon, C. Bordignon, A. Anichini, and G. Parmiani. 1995. Cytotoxic T lymphocyte clones from different patients display limited T-cell receptor variable gene usage in HLA-A2-restricted recognition of Melan-A/MART-1 melanoma antigen. Proc. Natl. Acad Sci. USA 92:5674.
56. 3 domain of HLA-A2. Nature 345:41.
57. Storkus, W. J., H. J. Zeh III, M. J. Maeurer, R. D. Salter, and M. T. Lotze. 1993. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J. Immunol. 151:3719.
58. Bodmer, H. C., F. M. Gotch, and A. J. McMichael. 1989. Class I cross-restricted T cells reveal low responder allele due to processing of viral antigen. Nature 337:653.
59. Holmes, N., and P. Parham. 1985. Exon shuffling in vivo can generate novel class I MHC molecules. EMBO J. 4:2849.